https://www.biospace.com/employer/3075213/compass-pathways Compass Pathways en-US Wed, 04 May 2022 15:14:02 GMT https://www.biospace.com/progress-in-biliary-tract-cancers-update Hayley Shasteen Compass and AstraZeneca have both provided updates to their clinical therapeutic programs focused on biliary tract cancers. Wed, 04 May 2022 15:14:02 GMT https://www.biospace.com/progress-in-biliary-tract-cancers-update https://www.biospace.com/psychedelic-medicine-takes-another-step-forward-with-compass-twin-updates George Budwell Compass' twin clinical updates regarding its lead candidate spotlight the promise of psychedelic medicine. Thu, 08 Dec 2022 16:10:39 GMT https://www.biospace.com/psychedelic-medicine-takes-another-step-forward-with-compass-twin-updates https://www.biospace.com/compass-pathways-psilocybin-treatment-well-tolerated-in-phase-ii-ptsd-trial Kate Goodwin The biotech’s investigational COMP360 psilocybin treatment showed positive safety and tolerability with no serious adverse events in a mid-stage study of people with post-traumatic stress disorder. Wed, 20 Dec 2023 21:55:15 GMT https://www.biospace.com/compass-pathways-psilocybin-treatment-well-tolerated-in-phase-ii-ptsd-trial https://www.biospace.com/compass-pathways-is-granted-new-us-patent-for-crystalline-psilocybin COMPASS Pathways plc (Nasdaq: CMPS) (“COMPASS”), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that it has been granted its fourth patent by the US Patent and Trademark Office (USPTO). Tue, 19 Oct 2021 11:06:06 GMT https://www.biospace.com/compass-pathways-is-granted-new-us-patent-for-crystalline-psilocybin https://www.biospace.com/compass-pathways-granted-fifth-us-patent-for-crystalline-psilocybin COMPASS Pathways plc (Nasdaq: CMPS) (“COMPASS”), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that it has been granted its fifth patent by the US Patent and Trademark Office (USPTO). Tue, 23 Nov 2021 12:06:08 GMT https://www.biospace.com/compass-pathways-granted-fifth-us-patent-for-crystalline-psilocybin https://www.biospace.com/compass-pathways-announces-further-positive-results-from-groundbreaking-phase-iib-trial-of-investigational-comp360-psilocybin-therapy-for-treatment-resistant-depression COMPASS Pathways plc today announced further results from its groundbreaking phase IIb clinical trial of COMP360 psilocybin therapy for treatment-resistant depression (TRD). Wed, 01 Dec 2021 12:06:04 GMT https://www.biospace.com/compass-pathways-announces-further-positive-results-from-groundbreaking-phase-iib-trial-of-investigational-comp360-psilocybin-therapy-for-treatment-resistant-depression https://www.biospace.com/compass-pathways-announces-positive-outcome-of-25mg-comp360-psilocybin-therapy-as-adjunct-to-ssri-antidepressants-in-open-label-treatment-resistant-depression-study COMPASS Pathways plc (Nasdaq: CMPS) (“COMPASS”), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health, today announced the results from its exploratory study of COMP360 psilocybin therapy in conjunction with SSRI use. Mon, 13 Dec 2021 12:06:05 GMT https://www.biospace.com/compass-pathways-announces-positive-outcome-of-25mg-comp360-psilocybin-therapy-as-adjunct-to-ssri-antidepressants-in-open-label-treatment-resistant-depression-study https://www.biospace.com/compass-pathways-announces-financial-results-for-the-fourth-quarter-and-full-year-2021-and-business-highlights COMPASS Pathways plc today reported its financial results for the fourth quarter and full year 2021 and gave an update on recent progress across its business. Thu, 24 Feb 2022 12:16:04 GMT https://www.biospace.com/compass-pathways-announces-financial-results-for-the-fourth-quarter-and-full-year-2021-and-business-highlights https://www.biospace.com/compass-pathways-to-fund-study-of-comp360-psilocybin-in-autistic-adults COMPASS Pathways plc (Nasdaq: CMPS) (“COMPASS”), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health, today announced it will be funding an investigator-initiated study that will use COMP360 psilocybin to explore how psilocybin affects specific brain pathways in autistic adults. Mon, 09 May 2022 11:06:07 GMT https://www.biospace.com/compass-pathways-to-fund-study-of-comp360-psilocybin-in-autistic-adults https://www.biospace.com/compass-pathways-to-participate-in-upcoming-citi-s-biopharma-virtual-co-panel-day-and-h-c-wainwright-global-investment-conference COMPASS Pathways plc (Nasdaq: CMPS), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that management will participate in two upcoming events. Thu, 12 May 2022 12:06:08 GMT https://www.biospace.com/compass-pathways-to-participate-in-upcoming-citi-s-biopharma-virtual-co-panel-day-and-h-c-wainwright-global-investment-conference